Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth

This article was originally published in Scrip

Executive Summary

Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.

Advertisement

Related Content

Portola's Xarelto/Eliquis Antidote To Be Refiled Next Year
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Boehringer Cuts 724 US Jobs To 'Reinvent' Pharma Business

Topics

Advertisement
UsernamePublicRestriction

Register

SC064997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel